With Streptococcus pneumoniae, moxifloxacin was 4-and 10-fold more effective than levofloxacin at restricting selection of resistant mutants and at killing resistant mutants, respectively. The selection frequency for first-step topoisomerase mutants was 1,000 times lower for moxifloxacin than for levofloxacin; this difference was lost when second-step mutants were selected.
CFU/150-mm-diameter plate) containing 10% sheep blood and either moxifloxacin (Bayer Corporation, West Haven, Conn.) or levofloxacin (R. W. Johnson Pharmaceutical Research Institute, Spring House, Pa.). Colonies were recovered and retested for growth on the selecting concentration of fluoroquinolone. DNA was isolated, quinolone-resistance-determining regions (QRDRs) were amplified, and nucleotide sequences were determined as described previously (1, 19) . Lethal activity was determined by incubating bacteria grown as liquid cultures (about 3 ϫ 10 7 CFU/ml) with fluoroquinolone at 37°C for 16 h. Aliquots from samples diluted into cold THB were spotted in triplicate onto drug-free BHI agar containing 10% sheep blood. Colonies were counted after overnight incubation at 37°C in the presence of 5% CO 2 .
Fluoroquinolone concentration dramatically affected the recovery of resistant mutants. As the concentration increased, the fraction of input cells recovered as mutant colonies dropped sharply, passed through an inflection point, and then continued to drop sharply (Fig. 1A) . When the QRDRs of genes encoding DNA gyrase (gyrA and gyrB) and DNA topoisomerase IV (parC and parE) were determined, GyrA variants (Ser-81 to Tyr and Ser-81 to Phe) were detected following moxifloxacin challenge, but only when 10 9 or more cells were tested. No mutation was found in gyrB, parC, or parE. With levofloxacin, ParC variants (Ser-79 to Tyr and Asp-83 to His) were recovered, but only when at least 1.8 ϫ 10 6 cells were tested. No mutation was detected in gyrA, gyrB, or parE. These data confirm that DNA gyrase is the primary target for moxifloxacin, while topoisomerase IV is the primary target for levofloxacin (15, 16) . The 1,000-fold difference in selection of target mutants has been observed with other pairs of fluoroquinolones (9) . It may reflect intrinsic differences between the targets. (With Escherichia coli, parC resistance mutations are codominant with the wild type, while gyrA mutations are recessive [10, 11] .) Non-topoisomerase mutants were recovered at low concentration: for some, reserpine lowered the fluoroquinolone MIC (not shown), indicating involvement of active efflux in reduced fluoroquinolone susceptibility (2) . The concentration at which no mutant was recovered when more than 10 10 cells were tested (mutant prevention concentration [MPC]) (8) was fourfold lower for moxifloxacin (Fig. 1A , arrowheads, and Table 1 ).
When second-step mutants were selected from a first-step parC resistance strain (KD2138) by using moxifloxacin or levofloxacin, the inflection region was more pronounced than with wild-type cells, and the MPC was higher (Fig. 1B) . Determination of QRDR nucleotide sequences in mutant DNA showed that gyrA parC double mutants were recovered (labeled arrows, Fig. 1B ). Similar phenomena were observed with a first-step gyrA resistance mutant (strain KD2139; Fig. 1C ). For both mutants, the MPC was higher for levofloxacin. This may reflect the inability of levofloxacin to kill resistant mutants at the MPC ( Fig. 2 and Table 1 ).
Several parameters obtained from the experiments described above allow quantitative comparison of moxifloxacin and levofloxacin (Table 1) . First, moxifloxacin MICs required to block colony formation by 99% (MIC 99 ; unlabeled arrows in Fig. 1) were 21, 62, and 17% of that of levofloxacin with wild-type, gyrA-resistant, and parC-resistant cells, respectively. The difference between the two mutants reflects the target preference of the two compounds (16, 17) . When the MPC is taken as the ability to restrict the growth of the most resistant mutant, moxifloxacin was four to five times more effective with wild-type cells and resistant mutants. With respect to lethal activity, moxifloxacin concentrations that allowed only 1% survival (LD 99 ) were 18, 8, and 9% that of levofloxacin with wild-type, gyrA-resistant, and parC-resistant cells, respectively. Collectively, these data show that moxifloxacin is intrinsically more active against wild-type and resistant S. pneumoniae.
From published pharmacokinetic measurements (4, 5, 18a), we calculated that drug concentrations in serum were above the MPC longer for moxifloxacin (38 h at the 400-mg dose) than for levofloxacin (8 h at the 500-mg dose; 18 h at the 750-mg dose). The area under the time-concentration curve that was above the MPC during 24 h for moxifloxacin was 4.5 times greater than that for levofloxacin (500-mg dose). Collectively, these data support the previous conclusion (1) that drug concentrations in serum are more likely to exceed the MPC of moxifloxacin than that of levofloxacin with S. pneumoniae. Additional work is required to provide estimates of available drug at the relevant sites of infection.
The acquisition of a first-step parC mutation by levofloxacin may have only a small effect on the ability of moxifloxacin to prevent growth (compare MIC 99 s in Table 1 ); however, it increases by several orders of magnitude the probability for acquiring a second mutation (compare Fig. 1A with B) . Thus, preservation of the effectiveness of new fluoroquinolones, such as moxifloxacin and gemifloxacin, may require avoiding the selective enrichment of first-step mutants by older compounds such as ciprofloxacin and levofloxacin.
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